Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Aug. 31 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND),
announced today that Larry Andrews, President and Chief Executive Officer of
the Company, is presenting at Rodman & Renshaw's 11th Annual Healthcare
Conference, which is being held in New York City from September 9 - 11 at the
New York Palace Hotel. Mr. Andrews will provide an update on the Company's
drug development activities and plans. Cipher's presentation will take place
on Friday, September 11, 2009 at 10:25 am ET in the Fahnestock Salon.
Cipher's presentation will be webcast live. To access the webcast go to:
http://www.wsw.com/webcast/rrshq15/dnd.to or www.cipherpharma.com.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals is a drug development company focused on
commercializing novel formulations of successful, currently marketed molecules
using advanced drug delivery technologies. Cipher's strategy is to in-license
products that incorporate proven drug delivery technologies and advance them
through the clinical development and regulatory approval stages, after which
the products are out-licensed to international partners. Because Cipher's
products are based on proven technology platforms applied to currently
marketed drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. The Company's
lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and
Drug Administration and Health Canada in the first quarter of 2006. The
product is being marketed in the United States by Kowa Pharmaceuticals America
under the label Lipofen(R). In addition, Cipher is developing formulations of
the pain reliever tramadol (tentative FDA approval in February 2009) and the
acne treatment isotretinoin (FDA approvable letter in April 2007).
Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and
has approximately 24 million shares outstanding. For more information, please
For further information:
For further information: Craig Armitage, Investor Relations, The Equicom
Group, (416) 815-0700 ext 278, (416) 815-0080 fax, email@example.com;
Larry Andrews, President and CEO, Cipher Pharmaceuticals, (905) 602-5840 ext
324, (905) 602-0628 fax, firstname.lastname@example.org